Cargando…
Commentary on the European Medicines Agency's extended mandate: Protecting public health in times of crisis and improving availability of medicines and medical devices
Autores principales: | Abed, Inga, Gonzalez‐Quevedo, Rosa, Mura, Manuela, Dias, Monica, da Rocha Dias, Silvy, García Burgos, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098850/ https://www.ncbi.nlm.nih.gov/pubmed/36345231 http://dx.doi.org/10.1111/bcp.15567 |
Ejemplares similares
-
Beyond “Intent‐to‐treat” and “Per protocol”: Improving assessment of treatment effects in clinical trials through the specification of an estimand
por: Pétavy, Frank, et al.
Publicado: (2020) -
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy
por: Tzogani, Kyriaki, et al.
Publicado: (2017) -
EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2017) -
EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma
por: Tzogani, Kyriaki, et al.
Publicado: (2018) -
UK Guidelines on the Diagnosis and Treatment of Breast Implant‐Associated Anaplastic Large Cell Lymphoma on behalf of the Medicines and Healthcare products Regulatory Agency Plastic, Reconstructive and Aesthetic Surgery Expert Advisory Group
por: Turton, Philip, et al.
Publicado: (2020)